Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Principia Biopharma
Principia Biopharma
Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts
Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts
Fierce Biotech
Sanofi
Denali
Kymab
Principia Biopharma
Flag link:
Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds
Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds
Fierce Biotech
Sanofi
M&A
earnings
Ablynx
Principia Biopharma
Flag link:
Sanofi’s Principia purchase fails its first test
Sanofi’s Principia purchase fails its first test
EP Vantage
Sanofi
rilzabrutinib
Principia Biopharma
clinical trials
pemphigus vulgaris
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia
Pharmaceutical Business Review
rilzabrutinib
fast track
FDA
Sanofi
Principia Biopharma
chronic immune thrombocytopenia
Flag link:
Gilead rescues biopharma’s takeout scene
Gilead rescues biopharma’s takeout scene
EP Vantage
M&A
Gilead Sciences
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Nestle
Aimmune
Tizona Therapeutics
Flag link:
Sanofi, seeking control of key drug, to buy Principia for $3.7B
Sanofi, seeking control of key drug, to buy Principia for $3.7B
BioPharma Dive
Sanofi
Principia Biopharma
M&A
multiple sclerosis
MS
SAR442168
Flag link:
Sanofi has a $50B biotech buyout budget, with Principia top of the list: report
Sanofi has a $50B biotech buyout budget, with Principia top of the list: report
Fierce Biotech
Sanofi
M&A
Principia Biopharma
Flag link:
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Flag link:
Multiple sclerosis “win” makes the Principia shorts squirm
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Principia Biopharma
SAR442168
MS
multiple sclerosis
Flag link:
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Adrangi mounts short attack on 'worthless' drugs of Sanofi ally
Fierce Biotech
Principia Biopharma
Sanofi
autoimmune disease
Kerrisdale Capital
Flag link:
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
AbbVie
Principia Biopharma
PRN1008
pemphigus vulgaris
Flag link:
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Endpoints
AbbVie
Principia Biopharma
inflammatory diseases
autoimmune disease
Flag link:
Principia jumps after $106.3M IPO
Principia jumps after $106.3M IPO
BioCentury
Principia Biopharma
IPOs
Flag link:
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug
Principia Sets IPO Terms as It Eyes Late-Stage Studies for Lead Drug
Xconomy
Principia Biopharma
IPOs
Flag link:
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
AbbVie, Sanofi-backed Principia offers an $86M IPO after burning through $148M for pipeline work
Endpoints
IPOs
Principia Biopharma
Sanofi
AbbVie
PRN1008
autoimmune disease
Flag link:
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Sanofi bolsters its position on multiple sclerosis with a $765M BTK licensing deal
Endpoints
Sanofi
multiple sclerosis
MS
Principia Biopharma
Flag link: